Core Viewpoint - Aptose Biosciences Inc. has received a recommendation from Institutional Shareholder Services (ISS) for shareholders to vote "FOR" the special resolution to approve the acquisition arrangement with Hanmi Pharmaceutical Co. Ltd. [1][2] Transaction Details - The arrangement involves Hanmi and its subsidiary acquiring all outstanding common shares of Aptose not owned by them, with shareholders receiving C$2.41 in cash per share, representing a 28% premium over the 30-day volume-weighted average price (VWAP) of C$1.88 [3] - The transaction is subject to customary closing conditions, including court approval and approval from the Toronto Stock Exchange (TSX) [9] Meeting Information - A special meeting for shareholders to approve the arrangement and continuance has been reconvened for March 31, 2026, at 11:00 a.m. (EST), to be held virtually [4] - The proxy voting deadline is set for March 27, 2026, at 11:00 a.m. (Eastern time) [7] Shareholder Communication - Aptose has filed a definitive proxy statement with the SEC and mailed it to all shareholders, providing necessary voting materials [5] - Morrow Sodali (Canada) Ltd. has been retained to assist with shareholder communications and proxy solicitation [10] Company Overview - Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [10]